טוען...
Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies
BACKGROUND: Rituximab (RTX), a monoclonal antibody that selectively binds to CD20+ B cells, showed favorable outcomes in patients with idiopathic inflammatory myopathies (IIM) in small case series, but the evidence is still not enough. Our goal was to determine the efficacy and safety of RTX for Kor...
שמור ב:
| הוצא לאור ב: | J Korean Med Sci |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
The Korean Academy of Medical Sciences
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7521958/ https://ncbi.nlm.nih.gov/pubmed/32989931 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3346/jkms.2020.35.e335 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|